Evidence map›Paper›PMID 34922480›Full record

ArticleBMC cancer2021

Subtype-Independent ANP32E Reduction During Breast Cancer Progression in Accordance with Chromatin Relaxation.

Garrett L Ruff, Kristin E Murphy, Zachary R Smith, Paula M Vertino, Patrick J Murphy

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Garrett L RuffDepartment of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY, 14642, USA.
Kristin E MurphyDepartment of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY, 14642, USA.
Zachary R SmithDepartment of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY, 14642, USA.
Paula M Vertino *Department of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY, 14642, USA.
Patrick J Murphy *Department of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY, 14642, USA. Patrick_Murphy@URMC.Rochester.edu.ORCID http://orcid.org/0000-0002-0880-392X
University of Rochester Medical Center · US

Funding

Function of Chromatin Features in Cellular ProgrammingR35GM137833 · NIGMS · UNIVERSITY OF ROCHESTER · PI Patrick J. Murphy · 2020 to 2026
$2.8M
Relaxed Polymerase Pausing as a Driver of Epigenetic Plasticity and Cancer Cell InvasionR01CA250531 · NCI · UNIVERSITY OF ROCHESTER · PI VERTINO, PAULA M. · 2021 to 2025
$2.2M
NCI NIH HHS R01 CA250531NIGMS NIH HHS R35 GM137833NIH HHS R01-CA250531NIH HHS R35-GM137833
6 · The paper itself

Abstract

backgroundChromatin state provides a clear decipherable blueprint for maintenance of transcriptional patterns, exemplifying a mitotically stable form of cellular programming in dividing cells. In this regard, genomic studies of chromatin states within cancerous tissues have the potential to uncover novel aspects of tumor biology and unique mechanisms associated with disease phenotypes and outcomes. The degree to which chromatin state differences occur in accordance with breast cancer features has not been established.

methodsWe applied a series of unsupervised computational methods to identify chromatin and molecular differences associated with discrete physiologies across human breast cancer tumors.

resultsChromatin patterns alone are capable of stratifying tumors in association with cancer subtype and disease progression. Major differences occur at DNA motifs for the transcription factor FOXA1, in hormone receptor-positive tumors, and motifs for SOX9 in Basal-like tumors. We find that one potential driver of this effect, the histone chaperone ANP32E, is inversely correlated with tumor progression and relaxation of chromatin at FOXA1 binding sites. Tumors with high levels of ANP32E exhibit an immune response and proliferative gene expression signature, whereas tumors with low ANP32E levels appear programmed for differentiation.

conclusionsOur results indicate that ANP32E may function through chromatin state regulation to control breast cancer differentiation and tumor plasticity. This study sets a precedent for future computational studies of chromatin changes in carcinogenesis.

Indexed as

Gene Expression Regulation, NeoplasticBiomarkers, TumorBreastBreast NeoplasmsCell Line, TumorChromatinChromatin Immunoprecipitation SequencingDatasets as TopicDisease ProgressionFemaleHepatocyte Nuclear Factor 3-alphaHumansMolecular ChaperonesANP32E protein, humanBiomarkers, TumorChromatinFOXA1 protein, humanHepatocyte Nuclear Factor 3-alphaMolecular ChaperonesANP32EBioinformaticsBreast CancerChromatinEpigeneticsFOXA1

Identifiers

PMID34922480
PMCPMC8684129
OpenAlexW4200586811

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.